Mizuho’s Jared Holz on how to play the underperforming health care sector

Jared Holz, Mizuho Securities healthcare sector strategist, joins ‘The Exchange’ to discuss Insmed’s lung drug being greenlit by the FDA and his read on the healthcare sector.